Inogen Company Profile (NASDAQ:INGN)

About Inogen (NASDAQ:INGN)

Inogen logoInogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company's Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INGN
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.79 billion
  • Outstanding Shares: 20,581,000
Average Prices:
  • 50 Day Moving Avg: $80.71
  • 200 Day Moving Avg: $71.03
  • 52 Week Range: $44.19 - $88.61
  • Trailing P/E Ratio: 77.60
  • Foreward P/E Ratio: 68.86
  • P/E Growth: 2.48
Sales & Book Value:
  • Annual Revenue: $212.34 million
  • Price / Sales: 8.41
  • Book Value: $9.38 per share
  • Price / Book: 9.25
  • EBIDTA: $35.35 million
  • Net Margins: 7.70%
  • Return on Equity: 9.59%
  • Return on Assets: 7.81%
  • Current Ratio: 5.23%
  • Quick Ratio: 4.68%
  • Average Volume: 189,642 shs.
  • Beta: 1.07
  • Short Ratio: 5.42

Frequently Asked Questions for Inogen (NASDAQ:INGN)

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

How were Inogen's earnings last quarter?

Inogen Inc (NASDAQ:INGN) released its quarterly earnings results on Tuesday, May, 9th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.15. The firm had revenue of $52.50 million for the quarter, compared to analyst estimates of $49.06 million. Inogen had a return on equity of 9.59% and a net margin of 7.70%. The business's revenue was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.12 EPS. View Inogen's Earnings History.

Where is Inogen's stock going? Where will Inogen's stock price be in 2017?

5 brokerages have issued 12-month price targets for Inogen's stock. Their forecasts range from $60.00 to $96.00. On average, they expect Inogen's share price to reach $77.60 in the next year. View Analyst Ratings for Inogen.

What are analysts saying about Inogen stock?

Here are some recent quotes from research analysts about Inogen stock:

  • 1. According to Zacks Investment Research, "Inogen reported a solid first quarter of 2017, beating the Zacks Consensus Estimate on both the counts. Over the last three months, the company outperformed the broader industry in terms of price. However, rental revenue headwinds are a concern, thanks to private insurance rate reductions, higher provisions for rental revenue adjustments and lower net patient additions. Inogen generates a significant portion of its revenues from the International market. Volatility in foreign exchange rate is expected to mar the company’s top line in the coming quarters. Furthermore, the stock looks a bit overvalued at the moment when compared to the market at large. However, Inogen has provided a positive guidance for full-year 2017. The company’s unique direct-to-customer business model, an innovative product line and growing patient base are key catalysts in our view." (5/15/2017)
  • 2. Needham & Company LLC analysts commented, "INGN beat consensus revenue, EBITDA, and EPS in 1Q17. Management maintained its 2017 revenue and EBITDA guidance and raised its 2017 net income guidance. The revenue upside was driven by 49% growth in B2B more than offsetting 0% growth in DTC. We think that the strong 84% growth in domestic B2B provides further evidence that home medical equipment companies (HMEs) are increasingly adopting portable oxygen concentrators." (5/10/2017)
  • 3. Stifel Nicolaus analysts commented, "Inogen (INGN) reported 4Q16 after the close on February 28, 2017 with results better than our expectations. Revenue, Adjusted-EBITDA, and Net Income all exceeded our expectations. Management slightly raised its recently established 2017 guidance. In our view, INGN has a great longer-term story that should continue to evolve and grow as disruption occurs in the high cost delivery model of oxygen to those that need it. Maintain Hold and adjust target to $65 based on a range of valuation multiples." (3/1/2017)

Are investors shorting Inogen?

Inogen saw a increase in short interest in April. As of April 13th, there was short interest totalling 1,303,057 shares, an increase of 12.9% from the March 31st total of 1,154,024 shares. Based on an average daily volume of 149,865 shares, the short-interest ratio is presently 8.7 days.

Who are some of Inogen's key competitors?

Who owns Inogen stock?

Inogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.31%), Brown Capital Management LLC (7.06%), Vanguard Group Inc. (5.93%), Blair William & Co. IL (4.50%), TimesSquare Capital Management LLC (2.80%) and Dimensional Fund Advisors LP (2.45%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger, Scott Wilkinson and Timothy Petersen. View Institutional Ownership Trends for Inogen.

Who sold Inogen stock? Who is selling Inogen stock?

Inogen's stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Kalmar Investments Inc. DE, JPMorgan Chase & Co., Wellington Management Group LLP, Loomis Sayles & Co. L P, Next Century Growth Investors LLC, TimesSquare Capital Management LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Inogen stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.

Who bought Inogen stock? Who is buying Inogen stock?

Inogen's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., FMR LLC, Renaissance Technologies LLC, Vanguard Group Inc., Cabot Wealth Management Inc. and Morgan Stanley. View Insider Buying and Selling for Inogen.

How do I buy Inogen stock?

Shares of Inogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Inogen stock cost?

One share of Inogen stock can currently be purchased for approximately $86.76.

Analyst Ratings

Consensus Ratings for Inogen (NASDAQ:INGN) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $77.60 (10.56% downside)

Analysts' Ratings History for Inogen (NASDAQ:INGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Stifel NicolausBoost Price TargetHold -> Hold$65.00 -> $75.00HighView Rating Details
5/10/2017Needham & Company LLCReiterated RatingBuy$96.00HighView Rating Details
4/18/2017SidotiInitiated CoverageNeutral -> Neutral$79.00MediumView Rating Details
3/1/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/AView Rating Details
6/8/2016Leerink SwannReiterated RatingOutperform$60.00N/AView Rating Details
3/24/2016Piper Jaffray CompaniesInitiated CoverageNeutral$46.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Inogen (NASDAQ:INGN)
Earnings by Quarter for Inogen (NASDAQ:INGN)
Earnings History by Quarter for Inogen (NASDAQ:INGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.12$0.27$49.06 million$52.50 millionViewListenView Earnings Details
2/28/2017Q416$0.10$0.25$46.19 million$50.85 millionViewListenView Earnings Details
11/3/2016Q316$0.13$0.16$47.89 million$54.42 millionViewN/AView Earnings Details
8/4/2016Q216$0.20$0.25$52.44 million$54.57 millionViewN/AView Earnings Details
5/9/2016Q116$0.12$0.11$41.75 million$43.00 millionViewN/AView Earnings Details
3/14/2016Q415$0.07$0.19$29.10 million$40.40 millionViewN/AView Earnings Details
11/10/2015Q315$0.13$0.13$36.99 million$40.80 millionViewListenView Earnings Details
8/11/2015Q215$0.15$0.17$36.88 million$44.00 millionViewListenView Earnings Details
5/12/2015Q1$0.07$0.08$29.98 million$33.70 millionViewListenView Earnings Details
4/27/2015Q115$0.03$0.06$19.80 million$29.10 millionViewN/AView Earnings Details
11/11/2014Q3 2014$0.06$0.11$28.00 million$29.40 millionViewN/AView Earnings Details
8/12/2014Q214$0.07$0.11$23.93 million$30.40 millionViewN/AView Earnings Details
5/13/2014Q114$0.04$0.05$20.70 million$23.60 millionViewN/AView Earnings Details
3/27/2014Q4 13$0.02$0.89$18.71 million$19.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Inogen (NASDAQ:INGN)
2017 EPS Consensus Estimate: $0.93
2018 EPS Consensus Estimate: $1.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.10$0.15$0.13
Q2 20172$0.26$0.32$0.29
Q3 20172$0.28$0.30$0.29
Q4 20172$0.20$0.25$0.23
Q1 20182$0.22$0.23$0.23
Q2 20182$0.29$0.57$0.43
Q3 20182$0.32$0.37$0.35
Q4 20182$0.28$0.29$0.29
(Data provided by Zacks Investment Research)


Dividend History for Inogen (NASDAQ:INGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Inogen (NASDAQ:INGN)
Insider Ownership Percentage: 5.18%
Insider Trades by Quarter for Inogen (NASDAQ:INGN)
Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)
Insider Trades by Quarter for Inogen (NASDAQ:INGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Ray Benjamin M AndersonDirectorSell4,445$81.05$360,267.25View SEC Filing  
5/10/2017Alison BauerleinEVPSell6,666$83.24$554,877.84View SEC Filing  
4/24/2017Byron MyersEVPSell10,000$80.00$800,000.00View SEC Filing  
4/17/2017Matt ScribnerEVPSell2,500$75.28$188,200.00View SEC Filing  
3/15/2017Matt ScribnerEVPSell2,500$73.85$184,625.00View SEC Filing  
2/28/2017Brenton TaylorEVPSell3,750$70.07$262,762.50View SEC Filing  
1/17/2017Matt ScribnerEVPSell2,500$63.91$159,775.00View SEC Filing  
1/17/2017Raymond HuggenbergerCEOSell5,680$63.96$363,292.80View SEC Filing  
1/10/2017Brenton TaylorEVPSell5,105$65.31$333,407.55View SEC Filing  
1/3/2017Brenton TaylorEVPSell31,823$65.69$2,090,452.87View SEC Filing  
12/15/2016Raymond HuggenbergerCEOSell8,000$65.59$524,720.00View SEC Filing  
12/14/2016Matt ScribnerEVPSell2,500$65.13$162,825.00View SEC Filing  
12/1/2016Scott WilkinsonInsiderSell26,706$61.64$1,646,157.84View SEC Filing  
11/14/2016Matt ScribnerEVPSell2,500$63.80$159,500.00View SEC Filing  
10/17/2016Raymond HuggenbergerCEOSell7,089$56.24$398,685.36View SEC Filing  
10/12/2016Matt ScribnerEVPSell4,551$59.45$270,556.95View SEC Filing  
9/19/2016Matt ScribnerEVPSell4,551$60.18$273,879.18View SEC Filing  
9/16/2016Byron MyersVPSell6,200$60.04$372,248.00View SEC Filing  
9/9/2016Byron MyersVPSell3,800$60.07$228,266.00View SEC Filing  
8/18/2016Matt ScribnerEVPSell2,320$56.39$130,824.80View SEC Filing  
8/15/2016Raymond HuggenbergerCEOSell20,747$57.48$1,192,537.56View SEC Filing  
8/9/2016Byron MyersVPSell13,000$55.00$715,000.00View SEC Filing  
7/18/2016Matt ScribnerEVPSell4,102$50.46$206,986.92View SEC Filing  
7/18/2016Raymond HuggenbergerCEOSell20,747$50.41$1,045,856.27View SEC Filing  
6/16/2016Matt ScribnerEVPSell4,102$47.66$195,501.32View SEC Filing  
6/16/2016Raymond HuggenbergerCEOSell20,747$47.86$992,951.42View SEC Filing  
5/16/2016Matt ScribnerEVPSell4,102$43.82$179,749.64View SEC Filing  
5/16/2016Raymond HuggenbergerCEOSell20,746$44.18$916,558.28View SEC Filing  
4/15/2016Matt ScribnerEVPSell4,102$48.62$199,439.24View SEC Filing  
4/15/2016Raymond HuggenbergerCEOSell29,635$48.59$1,439,964.65View SEC Filing  
4/13/2016Brenton TaylorEVPSell6,500$48.00$312,000.00View SEC Filing  
4/6/2016Alison BauerleinCFOSell9,278$46.18$428,458.04View SEC Filing  
3/31/2016Alison BauerleinCFOSell4,360$44.33$193,278.80View SEC Filing  
2/16/2016Matt ScribnerEVPSell4,102$30.26$124,126.52View SEC Filing  
1/14/2016Matt ScribnerEVPSell4,102$34.73$142,462.46View SEC Filing  
12/14/2015Matt ScribnerEVPSell4,102$40.40$165,720.80View SEC Filing  
11/12/2015Matt ScribnerEVPSell4,102$44.52$182,621.04View SEC Filing  
10/26/2015Brenton TaylorEVPSell5,000$41.38$206,900.00View SEC Filing  
10/21/2015Raymond HuggenbergerCEOSell57,418$43.06$2,472,419.08View SEC Filing  
10/12/2015Matt ScribnerEVPSell4,102$44.06$180,734.12View SEC Filing  
10/1/2015Alison BauerleinCFOSell10,185$47.94$488,268.90View SEC Filing  
9/25/2015Brenton TaylorEVPSell3,333$53.48$178,248.84View SEC Filing  
9/16/2015Byron MyersVPSell1,700$55.00$93,500.00View SEC Filing  
9/15/2015Raymond HuggenbergerCEOSell57,416$53.58$3,076,349.28View SEC Filing  
9/14/2015Byron MyersVPSell7,950$55.23$439,078.50View SEC Filing  
9/10/2015Matt ScribnerEVPSell4,102$53.30$218,636.60View SEC Filing  
9/1/2015Alison BauerleinCFOSell6,500$48.21$313,365.00View SEC Filing  
8/26/2015Scott WilkinsonEVPSell6,666$45.42$302,769.72View SEC Filing  
8/25/2015Brenton TaylorEVPSell3,333$46.84$156,117.72View SEC Filing  
8/25/2015Ray Benjamin M. AndersonDirectorSell5,658$46.36$262,304.88View SEC Filing  
5/28/2015Timothy PetersenDirectorSell337,081$37.44$12,620,312.64View SEC Filing  
5/26/2015Timothy PetersenDirectorSell54,258$37.05$2,010,258.90View SEC Filing  
5/22/2015Timothy PetersenDirectorSell86,889$37.09$3,222,713.01View SEC Filing  
5/21/2015Timothy PetersenDirectorSell134,300$37.81$5,077,883.00View SEC Filing  
5/19/2015Timothy PetersenDirectorSell115,700$37.25$4,309,825.00View SEC Filing  
5/18/2015Timothy PetersenDirectorSell58,987$37.35$2,203,164.45View SEC Filing  
3/5/2015Matt ScribnerEVPSell4,102$33.69$138,196.38View SEC Filing  
2/25/2015Brenton TaylorEVPSell15,687$33.87$531,318.69View SEC Filing  
2/23/2015Alison BauerleinCFOSell15,687$33.10$519,239.70View SEC Filing  
2/19/2015Raymond HuggenbergerCEOSell25,722$33.95$873,261.90View SEC Filing  
2/13/2015Scott WilkinsonEVPSell18,333$32.87$602,605.71View SEC Filing  
2/5/2015Matt ScribnerEVPSell4,102$30.66$125,767.32View SEC Filing  
2/3/2015Timothy PetersenDirectorSell17,000$30.25$514,250.00View SEC Filing  
2/2/2015Timothy PetersenDirectorSell99,000$30.88$3,057,120.00View SEC Filing  
1/29/2015Timothy PetersenDirectorSell601,000$31.95$19,201,950.00View SEC Filing  
1/26/2015Brenton TaylorEVPSell15,687$31.53$494,611.11View SEC Filing  
1/23/2015Alison BauerleinCFOSell15,687$31.53$494,611.11View SEC Filing  
1/20/2015Raymond HuggenbergerCEOSell25,722$31.63$813,586.86View SEC Filing  
1/5/2015Matt ScribnerEVPSell4,102$31.14$127,736.28View SEC Filing  
1/5/2015Versant Ventures Ii LlcMajor ShareholderSell7,946$30.98$246,167.08View SEC Filing  
12/30/2014Scott WilkinsonEVPSell962$30.50$29,341.00View SEC Filing  
12/29/2014Scott WilkinsonEVPSell15,735$30.52$480,232.20View SEC Filing  
12/24/2014Byron MyersVPSell7,514$30.07$225,945.98View SEC Filing  
12/23/2014Alison BauerleinCFOSell15,687$29.85$468,256.95View SEC Filing  
12/23/2014Byron MyersVPSell3,018$30.04$90,660.72View SEC Filing  
12/23/2014Versant Ventures Ii LlcMajor ShareholderSell9,785$29.74$291,005.90View SEC Filing  
12/22/2014Byron MyersVPSell11,801$30.06$354,738.06View SEC Filing  
12/22/2014Scott WilkinsonEVPSell1,033$30.31$31,310.23View SEC Filing  
12/19/2014Raymond HuggenbergerCEOSell25,722$28.98$745,423.56View SEC Filing  
12/11/2014Scott WilkinsonEVPSell14,700$25.25$371,175.00View SEC Filing  
12/3/2014Matt ScribnerEVPSell4,102$24.09$98,817.18View SEC Filing  
11/25/2014Brenton TaylorEVPSell15,687$24.71$387,625.77View SEC Filing  
11/21/2014Alison BauerleinCFOSell15,687$24.49$384,174.63View SEC Filing  
11/19/2014Raymond HuggenbergerCEOSell25,722$24.25$623,758.50View SEC Filing  
11/19/2014Versant Ventures Ii LlcMajor ShareholderSell28,225$24.77$699,133.25View SEC Filing  
11/18/2014Scott WilkinsonEVPSell2,233$25.21$56,293.93View SEC Filing  
11/18/2014Versant Ventures Ii LlcMajor ShareholderSell11,848$24.83$294,185.84View SEC Filing  
11/17/2014Versant Ventures Ii LlcMajor ShareholderSell5,343$24.89$132,987.27View SEC Filing  
11/14/2014Heather D RiderDirectorBuy3,000$25.00$75,000.00View SEC Filing  
11/14/2014Scott WilkinsonEVPSell1,100$25.15$27,665.00View SEC Filing  
11/14/2014Versant Ventures Ii LlcMajor ShareholderSell9,433$25.13$237,051.29View SEC Filing  
11/10/2014Versant Ventures Ii LlcMajor ShareholderSell2,992$24.42$73,064.64View SEC Filing  
11/7/2014Versant Ventures Ii LlcMajor ShareholderSell7,388$24.30$179,528.40View SEC Filing  
11/4/2014A/S NovoMajor ShareholderSell2,000,000$21.50$43,000,000.00View SEC Filing  
11/4/2014Raymond HuggenbergerCEOSell165,891$20.21$3,352,657.11View SEC Filing  
11/4/2014Timothy PetersenDirectorSell250,000$21.50$5,375,000.00View SEC Filing  
11/3/2014Matt ScribnerEVPSell4,102$24.08$98,776.16View SEC Filing  
10/29/2014Scott WilkinsonEVPSell18,333$22.41$410,842.53View SEC Filing  
10/27/2014Brenton TaylorEVPSell15,687$21.67$339,937.29View SEC Filing  
10/24/2014Versant Ventures Ii LlcMajor ShareholderSell4,647$20.76$96,471.72View SEC Filing  
10/23/2014Alison BauerleinCFOSell15,687$20.50$321,583.50View SEC Filing  
10/9/2014Versant Ventures Ii LlcMajor ShareholderSell1,900$20.83$39,577.00View SEC Filing  
10/8/2014Versant Ventures Ii LlcMajor ShareholderSell6,907$21.03$145,254.21View SEC Filing  
10/7/2014Timothy PetersenDirectorSell31,600$21.55$680,980.00View SEC Filing  
10/6/2014Timothy PetersenDirectorSell17,475$21.56$376,761.00View SEC Filing  
10/3/2014Timothy PetersenDirectorSell31,658$21.52$681,280.16View SEC Filing  
10/3/2014Ventures Lp Arboretum IIMajor ShareholderSell98,400$20.97$2,063,448.00View SEC Filing  
10/2/2014Timothy PetersenDirectorSell24,597$20.91$514,323.27View SEC Filing  
10/1/2014Matt ScribnerEVPSell8,204$20.25$166,131.00View SEC Filing  
10/1/2014Timothy PetersenDirectorSell42,145$20.61$868,608.45View SEC Filing  
9/30/2014Timothy PetersenDirectorSell84,500$20.23$1,709,435.00View SEC Filing  
9/24/2014Ventures Lp Arboretum IIMajor ShareholderSell83,500$20.34$1,698,390.00View SEC Filing  
9/23/2014Alison BauerleinCFOSell15,687$20.01$313,896.87View SEC Filing  
9/22/2014Raymond HuggenbergerCEOSell25,722$20.25$520,870.50View SEC Filing  
9/22/2014Timothy PetersenDirectorSell46,865$21.05$986,508.25View SEC Filing  
9/17/2014Timothy PetersenDirectorSell39,135$21.72$850,012.20View SEC Filing  
9/17/2014Ventures Lp Arboretum IIMajor ShareholderSell55,135$21.61$1,191,467.35View SEC Filing  
9/16/2014Timothy PetersenDirectorSell6,500$21.16$137,540.00View SEC Filing  
9/15/2014Byron MyersVPSell22,333$21.33$476,362.89View SEC Filing  
9/15/2014Scott WilkinsonEVPSell18,333$21.42$392,692.86View SEC Filing  
9/15/2014Timothy PetersenDirectorSell9,500$21.45$203,775.00View SEC Filing  
9/9/2014Versant Ventures Ii LlcMajor ShareholderSell7,388$23.25$171,771.00View SEC Filing  
3/7/2014Charles E LarsenDirectorSell26,201$14.88$389,870.88View SEC Filing  
2/20/2014A/S NovoInsiderSell617,000$14.88$9,180,960.00View SEC Filing  
2/20/2014Loren L McfarlandDirectorBuy3,125$16.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Inogen (NASDAQ:INGN)
Latest Headlines for Inogen (NASDAQ:INGN)
DateHeadline logoInogen Inc (INGN) Director Ray Benjamin M. Anderson Sells 4,445 Shares - May 22 at 10:26 PM logoInogen Is Trading Near Its 52-Week High... Here's What You Should Know - May 22 at 5:25 PM logoInogen Inc (INGN) Receives Average Rating of "Buy" from Analysts - May 22 at 7:56 AM logoHalyard Health-Sustainable Solutions Ink License Agreement - May 19 at 10:27 AM logoMcKesson (MCK) Beats Earnings Estimate in Q4, Revenues Miss - May 19 at 10:26 AM logoInogen Inc (INGN) Rating Increased to Strong-Buy at Zacks Investment Research - May 15 at 1:56 PM logoCan Inogen (INGN) Stock Continue to Grow Earnings? - May 15 at 10:52 AM logoStifel Nicolaus Raises Inogen Inc (INGN) Price Target to $75.00 - May 14 at 5:14 PM logoInogen Inc (INGN) EVP Alison Bauerlein Sells 6,666 Shares - May 12 at 4:27 PM logoFY2017 EPS Estimates for Inogen Inc (INGN) Increased by Analyst - May 12 at 12:52 PM logoWilliam Blair Research Analysts Cut Earnings Estimates for Inogen Inc (INGN) - May 12 at 10:11 AM logoFY2017 EPS Estimates for Inogen Inc Lifted by Analyst (INGN) - May 11 at 11:14 AM logoInogen Inc to Post Q2 2017 Earnings of $0.26 Per Share, Leerink Swann Forecasts (INGN) - May 11 at 8:34 AM logoInogen Inc (INGN) Cut to Sell at Zacks Investment Research - May 10 at 11:18 PM logoEdited Transcript of INGN earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 1:19 PM logoInogen Inc (INGN) Stock Rating Reaffirmed by Needham & Company LLC - May 10 at 7:58 AM logoInogen Inc (INGN) Releases Earnings Results, Beats Estimates By $0.13 EPS - May 9 at 10:44 PM logoInogen beats Street 1Q forecasts - May 9 at 6:45 PM logoInogen Announces First Quarter 2017 Financial Results - May 9 at 5:42 PM logo Analysts Expect Inogen Inc (INGN) Will Announce Quarterly Sales of $49.58 Million - May 7 at 9:22 AM logoShort Interest in Inogen Inc (INGN) Rises By 12.9% - May 6 at 7:44 AM logoInogen Inc (INGN) Expected to Post Earnings of $0.12 Per Share - May 5 at 10:14 AM logoSomewhat Negative Press Coverage Likely to Impact Inogen (INGN) Stock Price - May 2 at 9:30 PM logoCardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y - May 1 at 1:19 PM logoPositive News Coverage Very Unlikely to Impact Inogen (INGN) Stock Price - April 29 at 9:15 PM logoathenahealth (ATHN) Misses on Earnings & Revenues in Q1 - April 28 at 9:58 AM logoZimmer Biomet (ZBH) Beats on Q1 Earnings, Lowers Guidance - April 27 at 6:30 PM logoMead Johnson (MJN) Lags Q1 Earnings, Awaits Merger Closure - April 27 at 6:30 PM logoInogen (INGN) Earning Somewhat Favorable Press Coverage, Analysis Finds - April 26 at 11:08 PM logoByron Myers Sells 10,000 Shares of Inogen Inc (INGN) Stock - April 25 at 10:44 PM logoInogen to Announce First Quarter 2017 Results on Tuesday, May 9, 2017 - April 25 at 5:23 PM logoInogen Inc (INGN) Given Consensus Rating of "Buy" by Analysts - April 25 at 1:01 PM logoC.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up - April 24 at 9:46 AM logoInogen Inc (INGN) Now Covered by Sidoti - April 24 at 7:55 AM logoInogen (INGN) Getting Somewhat Favorable Press Coverage, AlphaOne Reports - April 22 at 2:25 PM logoBaxter Launches Drug Library Guide for Smart Infusion System - April 21 at 10:38 AM logoBull of the Day: Inogen (INGN) - April 20 at 11:26 AM logoQuest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View - April 20 at 11:26 AM logoInsider Selling: Inogen Inc (INGN) EVP Sells 2,500 Shares of Stock - April 19 at 10:45 PM logoAfter ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up - April 19 at 5:47 PM logoInogen (INGN) Earns Coverage Optimism Rating of -0.20 - April 19 at 12:11 PM logoSidoti Initiates Coverage on Inogen Inc (INGN) - April 18 at 4:26 PM logoAbbott Laboratories Agrees to Acquire Alere at Lower Price - April 17 at 10:51 AM logoInogen Inc (INGN) Expected to Post Quarterly Sales of $49.58 Million - April 16 at 9:42 AM logo$0.12 EPS Expected for Inogen Inc (INGN) This Quarter - April 14 at 10:12 AM logoHaemonetics' Plasma Group Strong, Blood Center Group a Drag - April 12 at 9:07 AM logoAccuray TomoTherapy System Starts Cancer Treatment in Africa - April 12 at 9:07 AM logoDaVita Banks on Acquisitions, Escalating Expenses a Concern - April 11 at 11:51 AM logoathenahealth (ATHN) Allies with CoverMyMeds for Faster ePA - April 11 at 11:51 AM logoZimmer Biomet (ZBH) Upgraded to Hold on Solid Prospects - April 10 at 5:38 PM



Inogen (INGN) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff